Insider · CIK 0001882909

Calvin Sandra

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001882909

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+2,500 sh	$27.50	+$68.8K	44,853
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+1,250 sh	$22.40	+$28K	46,103
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+1,625 sh	$20.46	+$33.2K	47,728
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−4,275 sh	$62.13	−$266K	43,453
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−800 sh	$62.85	−$50.3K	42,653
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−300 sh	$63.66	−$19.1K	42,353
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−2,500 sh	—	—	0
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−1,250 sh	—	—	3,750
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−1,625 sh	—	—	17,875
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+2,500 sh	$22.40	+$56K	51,580
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+6,250 sh	$8.93	+$55.8K	57,830
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+6,500 sh	$20.46	+$133K	64,330
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−22K sh	$41.07	−$903K	42,353
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−2,500 sh	—	—	5,000
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−6,250 sh	—	—	12,500
2026-04-14	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−6,500 sh	—	—	19,500
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−4,333 sh	$32.12	−$139K	49,080
2026-01-31	TVTXTravere Therapeutics, Inc.A Award	SVP, CHIEF ACCOUNTING OFFICER	AAward	+15.2K sh	—	—	53,413
2026-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	SVP, CHIEF ACCOUNTING OFFICER	AAward	+20.2K sh	—	—	20,160
2025-12-24	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−7,402 sh	$40.00	−$296K	38,233
2025-12-15	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−2,910 sh	$36.00	−$105K	45,635
2025-11-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+10K sh	$25.25	+$253K	64,410
2025-11-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+17.5K sh	$26.88	+$470K	81,910
2025-11-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+15K sh	$27.50	+$413K	96,910
2025-11-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+12.5K sh	$22.40	+$280K	109,410
2025-11-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+6,250 sh	$8.93	+$55.8K	115,660
2025-11-04	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−67.1K sh	$36.00	−$2.42M	48,545
2025-11-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−10K sh	—	—	0
2025-11-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−17.5K sh	—	—	0
2025-11-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−15K sh	—	—	2,500
2025-11-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−12.5K sh	—	—	7,500
2025-11-04	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−6,250 sh	—	—	18,750
2025-02-11	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+10K sh	$16.23	+$162K	73,654
2025-02-11	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−10K sh	$25.00	−$250K	63,654
2025-02-11	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+10K sh	$17.44	+$174K	73,654
2025-02-11	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−10K sh	$25.00	−$250K	63,654
2025-02-11	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+10K sh	$17.96	+$180K	73,654
2025-02-11	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−10K sh	$25.00	−$250K	63,654
2025-02-11	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+15K sh	$15.46	+$232K	78,654
2025-02-11	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−15K sh	$25.00	−$375K	63,654
2025-02-11	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−9,244 sh	$25.00	−$231K	54,410
2025-02-11	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−10K sh	—	—	0
2025-02-11	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−10K sh	—	—	0
2025-02-11	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−10K sh	—	—	0
2025-02-11	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	−15K sh	—	—	0
2025-02-03	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−3,348 sh	$20.12	−$67.4K	63,654
2025-01-31	TVTXTravere Therapeutics, Inc.A Award	SVP, CHIEF ACCOUNTING OFFICER	AAward	+13K sh	—	—	67,002
2025-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	SVP, CHIEF ACCOUNTING OFFICER	AAward	+26K sh	—	—	26,000
2025-01-22	TVTXTravere Therapeutics, Inc.S Sale	SVP, CHIEF ACCOUNTING OFFICER	SSale	−925 sh	$18.94	−$17.5K	54,002
2024-12-26	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	SVP, CHIEF ACCOUNTING OFFICER	MExercise/Conversion	+15K sh	$12.67	+$190K	69,927

Recent filings

Accepted (ET)
Sep 174
Calvin Sandra0001882909-26-000004
SEC(opens sec.gov)
Apr 164
Calvin Sandra0001882909-26-000003
SEC(opens sec.gov)
Feb 34
Calvin Sandra0001882909-26-000001
SEC(opens sec.gov)
Dec 294
Calvin Sandra0001882909-25-000008
SEC(opens sec.gov)

Companies

Travere Therapeutics, Inc.SVP, CHIEF ACCOUNTING OFFICERTVTX

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300

SAN DIEGO, CA, 92130